This is an enduring accredited activity focusing on improving clinicians knowledge and competence in the treatment of cholestatic liver diseases, including IBAT inhibitors. As a result of this activity, learners will be better able to: 1. Explain the rationale for new treatment strategies for the management of cholestatic pruritus; 2. Evaluate clinical trial data and safety profiles of new and emerging ileal bile acid transporter (IBAT) inhibitors; and, 3. Implement best practices for patient selection and initiation of IBAT inhibitor therapy.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
99% of listed courses are free
156 of 157 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General Internal Medicine
- General Pediatrics
- General Surgery
- Gynecologic Oncology
- Hematology
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Oncology
- Nephrology
- Neurocritical Care
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Urology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Microlearning
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedMar 12, 2026
-
Last day to claim creditMar 12, 2027 5 months left
-
Medscape, LLC From Uncertainty to Accuracy: Optimizing Outcomes in Adult Genetic Cholestatic Liver Diseases
-
Plexus Communications +1 Optimizing Checkpoint Inhibitor Therapy for Advanced Hepatobiliary Cancers
-
Catalyst Medical Education, LLC +1 Not Just a Nuisance: Assessing and Implementing Treatments for Cholestatic Itching as Part of Multimodal Care for Alagille Syndrome
-
Answers in CME Inc. (AiCME) Looking Ahead in Atopic Dermatitis: OX40/OX40L Mechanisms, Multidisciplinary Care, and Meaningful Patient Outcomes
-
Answers in CME Inc. (AiCME) From Symptoms to Stability: Emerging OX40/OX40L-Targeted Therapies, Durable AD Control, and Enhanced Quality of Life
-
Answers in CME Inc. (AiCME) From Screening to Specialized Care: Navigating Key Questions in AATD-Associated Liver Disease
